Allergan 2012 Q2 Sales Up Almost 5 Percent Compared to 2011 Q2

By
IRVINE, Calif.— Allergan, Inc. (NYSE: AGN) reported $1,467.4 million total product net sales for the second quarter ended June 30, 2012, an increase of 4.8 percent when compared to total product net sales in the second quarter of 2011. On a constant currency basis, total product net sales increased 8.7 percent compared to total product net sales in the second quarter of 2011. Total specialty pharmaceuticals net sales increased 5 percent, or 8.8 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2011. Total medical devices net sales increased 4 percent, or 8.3 percent on a constant currency basis, compared to total medical devices sales in the second quarter of 2011.

“In the second quarter, Allergan continued to deliver strong earnings growth in spite of the strong U.S. Dollar relative to virtually all major currencies,” said Dwight E.I. Pyott, Allergan’s chairman of the board, president and chief executive officer. “In addition, we continue to focus on identifying efficiencies so that we can continue to invest strongly in R&D to drive innovation.”

For the third quarter of 2012, Allergan expects total product net sales between $1,370 million and $1,445 million. For the full year of 2012, Allergan expects total net sales between $5,650 million and $5,800 million, total specialty pharmaceutical net sales between $4,740 million and $4,850 million, total medical devices net sales between $910 million and $950 million, Alphagan franchise product net sales between $420 million and $440 million, Lumigan franchise product net sales between $620 million and $640 million, and Restasis product net sales between $750 million and $780 million.